Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.38 |
| ▸ | ARG2 | P78540 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9554357 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2HIF1AARG1ARG2CYP1A2 | |
| SCHEMBL5053174 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2HIF1AFOLH1ARG1ARG2 | |
| SCHEMBL10938263 | 0.74 | CYP3A4 (0.42) | SMN1; SMN2HIF1ACYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL27515246 | 0.74 | SMN1; SMN2 (0.48) | SMN1; SMN2HIF1AARG1ARG2CYP1A2 | |
| SCHEMBL5051288 | 0.73 | SMN1; SMN2 (0.44) | SMN1; SMN2HIF1AFOLH1ARG1ARG2 | |
| SCHEMBL28561877 | 0.72 | SMN1; SMN2 (0.43) | SMN1; SMN2HIF1ACYP1A2CYP1A1CYP1B1 | |
| SCHEMBL4397841 | 0.72 | GRM2 (0.43) | SMN1; SMN2CYP1A2HDAC3HDAC4HDAC1 | |
| SCHEMBL5051190 | 0.71 | SMN1; SMN2 (0.46) | SMN1; SMN2HIF1AFOLH1ARG1ARG2 | |
| SCHEMBL9555278 | 0.70 | PTPN1 (0.47) | SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29048912 | 0.69 | MMP8 (0.46) | SMN1; SMN2ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992215-B2 | Thiol-based NAALADase inhibitors | GUILDFORD PHARMACEUTICALS INC. (US) | 2006-01-31 | — | — | US | claimed |
| US-20050085503-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC, | 2005-04-21 | — | — | US | claimed |
| WO-2002057222-A9 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARM INC (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030216468-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2003-11-20 | — | — | US | claimed |
| EP-1353903-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-10-22 | — | — | EP | claimed |
| US-20030105088-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2003-06-05 | — | — | US | claimed |
| WO-2002057222-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-07-25 | — | — | WO | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216468-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, RIMKLA | SMN1; SMN2 2613/4885HIF1A 947/4885FOLH1 6/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | SMN1; SMN2 3363/4885HIF1A 464/4885FOLH1 1/4885 |
| US-20030105088-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, RIMKLA | SMN1; SMN2 2613/4885HIF1A 947/4885FOLH1 6/4885 |
| US-20050085503-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, FOLH1 | SMN1; SMN2 2759/4885HIF1A 825/4885FOLH1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.